Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.64 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GAPDH | P04406 | 1/20 | 0.48 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982454 | 1.00 | ADORA3 (0.67) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL658005 | 1.00 | ADORA3 (0.67) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL5982465 | 1.00 | ADORA3 (0.67) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL6302264 | 0.89 | ADORA3 (0.66) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL13835070 | 0.89 | ADORA3 (0.66) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL24420487 | 0.89 | ADORA3 (0.66) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL5982751 | 0.89 | ADORA3 (0.55) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL5980703 | 0.89 | ADORA3 (0.55) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL5982757 | 0.89 | ADORA3 (0.55) | ADORA3ADORA2AHSPA5HSPA8RXFP1 | |
| SCHEMBL18952838 | 0.89 | ADORA3 (0.66) | ADORA3ADORA2AHSPA5HSPA8RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427864-B2 | Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients | EXOSOME DIAGNOSTICS, INC. (US) | 2022-08-30 | — | — | US | claimed |
| EP-3548635-B1 | METHODS TO DETECT MUTATIONS IN PLASMA USING EXOSOMAL RNA AND CELL FREE DNA FROM NON-SMALL CELL LUNG CANCER PATIENTS | EXOSOME DIAGNOSTICS INC (US) | 2021-04-28 | — | — | EP | claimed |
| EP-3548635-A1 | METHODS AND COMPOSITIONS TO DETECT MUTATIONS IN PLASMA USING EXOSOMAL RNA AND CELL FREE DNA FROM NON-SMALL CELL LUNG CANCER PATIENTS | Exosome Diagnostics, Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| WO-2018102162-A1 | METHODS AND COMPOSITIONS TO DETECT MUTATIONS IN PLASMA USING EXOSOMAL RNA AND CELL FREE DNA FROM NON-SMALL CELL LUNG CANCER PATIENTS | EXOSOME DIAGNOSTICS, INC. (US) | 2018-06-07 | — | — | WO | claimed |
| US-6831072-B2 | Such as 8-amino-2'deoxyadenosine by treating 8-azido-2'deoxyadenosine with aqueous solution of methylamine or dimethylamine; for targeting nucleic acids without amplification and less use of enzymes | CYGENE, INC. | 2004-12-14 | — | — | US | claimed |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | CYGENE, INC. | 2003-07-17 | — | — | US | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4692373-A1 | USE OF DETECTING METHYLATION LEVEL OF TXNRD1 GENE IN DIAGNOSIS AND/OR SCREENING OF ENDOMETRIAL CANCER | Beijing Youxun Yicheng Medical Equipment Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240392395-A1 | POLYPURINE REVERSE HOOGSTEEN HAIRPINS AND PARALLEL CLAMPS AND THEIR USE AS BIOSENSORS | UNIVERSITAT DE BARCELONA (ES) | 2024-11-28 | — | — | US | disclosed |
| WO-2024199228-A1 | USE OF DETECTING METHYLATION LEVEL OF TXNRD1 GENE IN DIAGNOSIS AND/OR SCREENING OF ENDOMETRIAL CANCER | 北京优迅医学检验实验室有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20240182906-A1 | GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT | Research Foundation to Cure AIDS, Inc. (US) | 2024-06-06 | — | — | US | disclosed |
| US-6831072-B2 | Such as 8-amino-2'deoxyadenosine by treating 8-azido-2'deoxyadenosine with aqueous solution of methylamine or dimethylamine; for targeting nucleic acids without amplification and less use of enzymes | CYGENE, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | CYGENE, INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003100099-A1 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | CYGENE, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | CYGENE, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | CYGENE, INC. | 2003-07-17 | — | — | US | disclosed |
| EP-1228243-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | Cygene, Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032924-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | ADORA3 1197/4885ADORA2A 1754/4885HSPA5 3248/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | ADORA3 1734/4885ADORA2A 2575/4885HSPA5 1485/4885 |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ADAR, NSUN2, RNGTT | ADORA3 324/4885ADORA2A 145/4885HSPA5 2122/4885 |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | DDX18, DDX1, ADAR | ADORA3 437/4885ADORA2A 250/4885HSPA5 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.